<VariationArchive VariationID="12164" VariationName="NM_000500.9(CYP21A2):c.332_339del (p.Gly111fs)" VariationType="Deletion" Accession="VCV000012164" Version="18" RecordType="classified" NumberOfSubmissions="10" NumberOfSubmitters="10" DateLastUpdated="2024-07-29" DateCreated="2013-04-04" MostRecentSubmission="2024-07-23">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="27203" VariationID="12164">
      <GeneList>
        <Gene Symbol="LOC106780800" FullName="CYP21A2 recombination region" GeneID="106780800" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>6p21.33</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="32037872" stop="32041144" display_start="32037872" display_stop="32041144" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NT_167247.2" start="3379909" stop="3383177" display_start="3379909" display_stop="3383177" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="CYP21A2" FullName="cytochrome P450 family 21 subfamily A member 2" GeneID="1589" HGNC_ID="HGNC:2600" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>6p21.33</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="32038415" stop="32041644" display_start="32038415" display_stop="32041644" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NT_113891.3" start="3476737" stop="3479966" display_start="3476737" display_stop="3479966" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NT_167245.2" start="3279823" stop="3283052" display_start="3279823" display_stop="3283052" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NT_167247.2" start="3380452" stop="3383677" display_start="3380452" display_stop="3383677" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NT_167249.2" start="3339605" stop="3342831" display_start="3339605" display_stop="3342831" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NT_167248.2" start="3261650" stop="3264877" display_start="3261650" display_stop="3264877" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="32006092" stop="32009446" display_start="32006092" display_stop="32009446" Strand="+" />
          </Location>
          <OMIM>613815</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000500.9(CYP21A2):c.332_339del (p.Gly111fs)</Name>
      <CanonicalSPDI>NC_000006.12:32039132:GAGACTAC:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>6p21.33</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="32039133" stop="32039140" display_start="32039133" display_stop="32039140" variantLength="8" positionVCF="32039132" referenceAlleleVCF="GGAGACTAC" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="32006910" stop="32006917" display_start="32006910" display_stop="32006917" variantLength="8" positionVCF="32006909" referenceAlleleVCF="GGAGACTAC" alternateAlleleVCF="G" />
      </Location>
      <OtherNameList>
        <Name>707-714delGAGACTAC</Name>
      </OtherNameList>
      <ProteinChange>G81fs</ProteinChange>
      <ProteinChange>G111fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.11" sequenceAccession="NC_000006" sequenceVersion="11" change="g.32006910_32006917del" Assembly="GRCh37">
            <Expression>NC_000006.11:g.32006910_32006917del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.12" sequenceAccession="NC_000006" sequenceVersion="12" change="g.32039133_32039140del" Assembly="GRCh38">
            <Expression>NC_000006.12:g.32039133_32039140del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007941.3" sequenceAccession="NG_007941" sequenceVersion="3" change="g.5829_5836del">
            <Expression>NG_007941.3:g.5829_5836del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_045215.1" sequenceAccession="NG_045215" sequenceVersion="1" change="g.1362_1369del">
            <Expression>NG_045215.1:g.1362_1369del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000500.9" sequenceAccession="NM_000500" sequenceVersion="9" change="c.332_339del" MANESelect="true">
            <Expression>NM_000500.9:c.332_339del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000491.4" sequenceAccession="NP_000491" sequenceVersion="4" change="p.Gly111fs">
            <Expression>NP_000491.4:p.Gly111fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001128590.4" sequenceAccession="NM_001128590" sequenceVersion="4" change="c.242_249del">
            <Expression>NM_001128590.4:c.242_249del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001122062.3" sequenceAccession="NP_001122062" sequenceVersion="3" change="p.Gly81fs">
            <Expression>NP_001122062.3:p.Gly81fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001368143.2" sequenceAccession="NM_001368143" sequenceVersion="2" change="c.-74_-67del">
            <Expression>NM_001368143.2:c.-74_-67del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001368144.2" sequenceAccession="NM_001368144" sequenceVersion="2" change="c.-74_-67del">
            <Expression>NM_001368144.2:c.-74_-67del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001623" Type="5 prime UTR variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_829" sequenceAccession="LRG_829">
            <Expression>LRG_829:g.5829_5836del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_829t1" sequenceAccession="LRG_829t1">
            <Expression>LRG_829t1:c.332_339del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_829p1" sequenceAccession="LRG_829p1" change="p.Gly111fs">
            <Expression>LRG_829p1:p.Gly111fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000500.7" sequenceAccession="NM_000500" sequenceVersion="7" change="c.332_339delGAGACTAC">
            <Expression>NM_000500.7:c.332_339delGAGACTAC</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000500.9" sequenceAccession="NM_000500" sequenceVersion="9" change="c.332_339delGAGACTAC" MANESelect="true">
            <Expression>NM_000500.9:c.332_339delGAGACTAC</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA341188" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="613815.0015" DB="OMIM" />
        <XRef Type="rs" ID="387906510" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000500.9(CYP21A2):c.332_339del (p.Gly111fs) AND Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency" Accession="RCV000012946" Version="9">
        <ClassifiedConditionList TraitSetID="3295">
          <ClassifiedCondition DB="MedGen" ID="C2936858">Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-07-16" SubmissionCount="6">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000500.9(CYP21A2):c.332_339del (p.Gly111fs) AND not provided" Accession="RCV000711378" Version="13">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-09-13" SubmissionCount="4">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-09-13" NumberOfSubmissions="10" NumberOfSubmitters="10" DateCreated="2013-04-04" MostRecentSubmission="2024-07-23">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10857554</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12788880</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17275379</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20970527</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23359698</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25121463</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25227725</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25481255</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25538881</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26804566</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">2827462</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">30995443</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31446012</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">31586465</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3260033</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">35079965</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7749410</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8081391</ID>
        </Citation>
        <Citation Type="review" Abbrev="GeneReviews">
          <ID Source="PubMed">20301350</ID>
          <ID Source="BookShelf">NBK1171</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3295" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="10963" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency</ElementValue>
                <XRef ID="MONDO:0008728" DB="MONDO" />
                <XRef ID="90794" DB="Orphanet" />
                <XRef ID="717261006" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Congenital adrenal hyperplasia due to 21-hydroxylase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">CYP21 deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia</ElementValue>
                <XRef ID="NBK1171" DB="GeneReviews" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="12665" />
                <XRef ID="12665" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">21-hydroxylase deficiency (21-OHD) is the most common cause of congenital adrenal hyperplasia (CAH), a family of autosomal recessive disorders involving impaired synthesis of cortisol from cholesterol by the adrenal cortex. In 21-OHD CAH, excessive adrenal androgen biosynthesis results in virilization in all individuals and salt wasting in some individuals. A classic form with severe enzyme deficiency and prenatal onset of virilization is distinguished from a non-classic form with mild enzyme deficiency and postnatal onset. The classic form is further divided into the simple virilizing form (~25% of affected individuals) and the salt-wasting form, in which aldosterone production is inadequate (â‰¥75% of individuals). Newborns with salt-wasting 21-OHD CAH are at risk for life-threatening salt-wasting crises. Individuals with the non-classic form of 21-OHD CAH present postnatally with signs of hyperandrogenism; females with the non-classic form are not virilized at birth.</Attribute>
                <XRef ID="NBK1171" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301350</ID>
                <ID Source="BookShelf">NBK1171</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2011">
                <URL>https://www.ncbi.nlm.nih.gov/books/NBK55827/bin/CAH.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Congenital Adrenal Hyperplasia, 2011</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.ncbi.nlm.nih.gov/books/NBK55827/bin/Visio-NBS_Elevated_17OHP.pdf</URL>
                <CitationText>American College of Medical Genetics Algorithm, Congenital Adrenal Hyperplasia, 2009</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ESCGS, 2010">
                <ID Source="pmc">2936060</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2018">
                <ID Source="PubMed">30272171</ID>
                <ID Source="pmc">6456929</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/Elevated-17-OHP-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Congenital Adrenal Hyperplasia (Elevated 17-OHP), 2009</CitationText>
              </Citation>
              <XRef ID="90794" DB="Orphanet" />
              <XRef ID="C2936858" DB="MedGen" />
              <XRef ID="MONDO:0008728" DB="MONDO" />
              <XRef Type="MIM" ID="201910" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="33190" SubmissionDate="2013-04-29" DateLastUpdated="2013-04-04" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="613815.0015_ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY, SALT-WASTING TYPE" title="CYP21A2, 8-BP DEL_ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY, SALT-WASTING TYPE" />
        <ClinVarAccession Accession="SCV000033190" DateUpdated="2013-04-04" DateCreated="2013-04-04" Type="SCV" Version="1" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2003-06-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">By hybridization with specific oligonucleotide probes, White et al. (1988) showed an 8-bp deletion of nucleotides 707-714 in exon 3, typical of CYP21P, which prevents synthesis of the protein by a frameshift and causes the salt-wasting type of congenital adrenal hyperplasia. This mutation is present in about 8% of the salt-wasting CAH (201910) cases.</Attribute>
              <Citation>
                <ID Source="PubMed">3260033</ID>
              </Citation>
              <XRef DB="OMIM" ID="201910" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">See 613815.0006 and Lee et al. (2003).</Attribute>
              <Citation>
                <ID Source="PubMed">12788880</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CYP21A2" />
          </GeneList>
          <Name>CYP21A2, 8-BP DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">8-BP DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="613815.0015" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY, SALT-WASTING TYPE</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="145534" SubmissionDate="2013-04-30" DateLastUpdated="2013-10-01" DateCreated="2013-10-01">
        <ClinVarSubmissionID localKey="NM_000500.5:c.332_339del(8-bp deletion in exon 3 or 707_714del)_NBK1171" title="NM_000500.5:c.332_339del(8-bp deletion in exon 3 or 707_714del) and 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia" />
        <ClinVarAccession Accession="SCV000086798" DateUpdated="2013-10-01" DateCreated="2013-10-01" Type="SCV" Version="1" SubmitterName="GeneReviews" OrgID="500062" OrganizationCategory="resource" OrgAbbreviation="GeneReviews" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2013-08-29">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>pathologic</GermlineClassification>
          <Comment>Converted during submission to Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>not provided</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <Purpose>Assert pathogenicity</Purpose>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000500.5:c.332_339del(8-bp deletion in exon 3 or 707_714del)</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia</ElementValue>
            </Name>
            <XRef DB="GeneReviews" ID="NBK1171" />
            <XRef DB="OMIM" ID="201910" Type="MIM" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2354598" SubmissionDate="2020-06-18" DateLastUpdated="2020-07-03" DateCreated="2020-04-06">
        <ClinVarSubmissionID localKey="141880|OMIM:201910" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001194143" DateUpdated="2020-07-03" DateCreated="2020-04-06" Type="SCV" Version="2" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <ReplacedList>
          <Replaced Accession="SCV000677908" DateChanged="2020-07-01" Version="1">
            <Comment Type="MergeComment">SCV000677908 was merged into SCV001194143 to remove duplication.</Comment>
          </Replaced>
        </ReplacedList>
        <Classification DateLastEvaluated="2019-12-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25227725</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8081391</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23359698</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25121463</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12788880</ID>
          </Citation>
          <Comment>NM_000500.7(CYP21A2):c.332_339del8(G111Vfs*21) is classified as pathogenic in the context of congenital adrenal hyperplasia, CYP21A2-related and is associated with classic disease. Sources cited for classification include the following: PMID 25227725, 8081391, 23359698, 25121463 and 12788880 . Classification of NM_000500.7(CYP21A2):c.332_339del8(G111Vfs*21) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Women's Health Autosomal Recessive and X-Linked Classification Criteria (2019)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/vlxza0ea/myriad_women_s_health_autosomal_recessive_and_x-linked_classification_criteria_2019_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CYP21A2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="6" alternateAllele="G" referenceAllele="GGAGACTAC" start="32006909" stop="32006917" variantLength="9" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="201910" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6849778</SubmissionName>
          <SubmissionName>SUB7605676</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7183220" SubmissionDate="2023-03-16" DateLastUpdated="2023-03-26" DateCreated="2023-03-26">
        <ClinVarSubmissionID localKey="NM_000500.7:c.332_339delGAGACTAC|MedGen:C0852654" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003845012" DateUpdated="2023-03-26" DateCreated="2023-03-26" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">8081391</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17275379</ID>
          </Citation>
          <Comment>Variant summary: CYP21A2 c.332_339delGAGACTAC (p.Gly111ValfsX21) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 246380 control chromosomes (gnomAD). c.332_339delGAGACTAC has been reported in the literature in multiple compound heterozygous and homozygous individuals affected with Congenital Adrenal Hyperplasia (Wilson_2007, Milacic_2015). These data indicate that the variant is very likely to be associated with disease. Functional studies report experimental evidence evaluating an impact on protein function and results in null activity based on in vitro studies. Five ClinVar submitters (evaluation after 2014) cite this variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CYP21A2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000500.7:c.332_339delGAGACTAC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0852654" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12956415</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7512058" SubmissionDate="2023-07-17" DateLastUpdated="2023-07-22" DateCreated="2023-07-22">
        <ClinVarSubmissionID localKey="53624084|OMIM:201910" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004013232" DateUpdated="2023-07-22" DateCreated="2023-07-22" Type="SCV" Version="1" SubmitterName="Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center" OrgID="1019" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-19">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>PVS1, PS3</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CYP21A2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000500.9:c.332_339del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="201910" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13685737</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4012247" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2022-01-01">
        <ClinVarSubmissionID localKey="S8983|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002046176" DateUpdated="2024-01-06" DateCreated="2022-01-01" Type="SCV" Version="3" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12788880</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31446012</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31586465</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30995443</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20970527</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25121463</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25227725</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25538881</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23359698</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25481255</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26804566</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2827462</ID>
          </Citation>
          <Comment>The c.332_339del (p.Gly111Valfs*21) (also known as c.332_339del8 (G110del8nt)) variant alters the translational reading frame of the CYP21A2 mRNA and causes the premature termination of CYP21A2 protein synthesis. This pathogenic variant is associated with salt wasting CAH (PMIDs: 2827462 (1988), 23359698 (2013), and 25227725 (2014)). Based on the available information, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000500.7:c.332_339del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10813355</SubmissionName>
          <SubmissionName>SUB12490872</SubmissionName>
          <SubmissionName>SUB14108248</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1639973" SubmissionDate="2024-01-03" DateLastUpdated="2024-01-26" DateCreated="2018-10-20">
        <ClinVarSubmissionID localKey="A295|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000841741" DateUpdated="2024-01-26" DateCreated="2018-10-20" Type="SCV" Version="4" SubmitterName="Athena Diagnostics" OrgID="1012" OrganizationCategory="laboratory" OrgAbbreviation="ADX" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-07">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12788880</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31446012</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">31586465</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">30995443</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20970527</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25121463</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25227725</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25538881</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23359698</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25481255</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26804566</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2827462</ID>
          </Citation>
          <Comment>This variant is expected to result in the loss of a functional protein. Frequency data for this variant in the general population cannot be distinguished from that of the CYP21P pseudogene, and are therefore uninformative in assessment of variant pathogenicity. In multiple individuals, this variant has been seen in trans with other recessive pathogenic variants in CYP21A2, suggesting this variant is also pathogenic. In some published literature, this variant is referred to as c.329_336del, g.707_714del, p.Gly110fs, or as the 8 bp deletion in exon 3.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Athena Diagnostics Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000500.7:c.332_339del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10229685</SubmissionName>
          <SubmissionName>SUB12478070</SubmissionName>
          <SubmissionName>SUB14108777</SubmissionName>
          <SubmissionName>SUB4481681</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3961519" SubmissionDate="2024-01-26" DateLastUpdated="2024-02-04" DateCreated="2021-11-29">
        <ClinVarSubmissionID localKey="037b553fc42a0b6715aaf17f3019e4bf09a52cd32b46a64baa1c849d1d432d6a|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002018111" DateUpdated="2024-02-04" DateCreated="2021-11-29" Type="SCV" Version="3" SubmitterName="Revvity Omics, Revvity" OrgID="167595" OrganizationCategory="laboratory" OrgAbbreviation="PKIG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-09-13">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000500.9:c.332_339del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10694847</SubmissionName>
          <SubmissionName>SUB12926214</SubmissionName>
          <SubmissionName>SUB14173319</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4204504" SubmissionDate="2023-01-10" DateLastUpdated="2023-02-07" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="3551479|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002182512" DateUpdated="2023-02-07" DateCreated="2022-03-28" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-10-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10857554</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">7749410</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8081391</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23359698</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25227725</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26804566</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Gly111Valfs*21) in the CYP21A2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CYP21A2 are known to be pathogenic (PMID: 10857554). The frequency data for this variant in the population databases (gnomAD) is considered unreliable due to the presence of homologous sequence, such as pseudogenes or paralogs, in the genome. This premature translational stop signal has been observed in individual(s) with classic salt-wasting, simple virilizing, and non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (PMID: 7749410, 8081391, 23359698, 25227725, 26804566). This variant is also known as 706del8, 707_714del8, E3del8bp, c.711_718delGAGACTAC. ClinVar contains an entry for this variant (Variation ID: 12164). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CYP21A2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000006.11:g.32006910_32006917del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9874007" SubmissionDate="2024-07-18" DateLastUpdated="2024-07-23" DateCreated="2024-07-23">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_000500_9_CYP21A2_c_332_339delGAGACTAC" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV005086882" DateUpdated="2024-07-23" DateCreated="2024-07-23" Type="SCV" Version="1" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">26804566</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">35079965</ID>
          </Citation>
          <Comment>Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (MIM#201910) and hyperandrogenism nonclassic type due to 21-hydroxylase deficiency (MIM#201910). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous (according to Fulgent Genetics report). (I) 0304 - Variant is present in gnomAD &lt;0.01 for a recessive condition (v3: 16 heterozygotes, 0 homozygotes). However, please note this variant has failed a filter used for quality control in gnomAD v3. (SP) 0701 - Other variants predicted to result in NMD comparable to the one identified in this case have very strong previous evidence for pathogenicity (DECIPHER). (SP) 0801 - This variant has very strong previous evidence of pathogenicity in unrelated individuals. It has been detected in multiple compound heterozygous patients (ClinVar, PMIDs: 35079965, 26804566). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CYP21A2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_21063</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000500.9:c.332_339delGAGACTAC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="201910" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_45</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2354598" TraitType="Disease" MappingType="XRef" MappingValue="201910" MappingRef="OMIM">
        <MedGen CUI="C2936858" Name="Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7512058" TraitType="Disease" MappingType="XRef" MappingValue="201910" MappingRef="OMIM">
        <MedGen CUI="C2936858" Name="Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9874007" TraitType="Disease" MappingType="XRef" MappingValue="201910" MappingRef="OMIM">
        <MedGen CUI="C2936858" Name="Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="145534" TraitType="Disease" MappingType="Name" MappingValue="21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia" MappingRef="Preferred">
        <MedGen CUI="C2936858" Name="Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4012247" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4204504" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3961519" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="33190" TraitType="Disease" MappingType="Name" MappingValue="ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY, SALT-WASTING TYPE" MappingRef="Preferred">
        <MedGen CUI="C2936858" Name="Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1639973" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7183220" TraitType="Disease" MappingType="XRef" MappingValue="C0852654" MappingRef="MedGen">
        <MedGen CUI="C2936858" Name="Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

